IPCA Laboratories

IPCA Laboratories Diluted EPS

The Diluted Earnings per Share of IPCA Laboratories (IPCALAB.NS) as of Oct 29, 2026 is 44.98 INR. In the previous year, Diluted Earnings per Share was 29.08 INR — a change of 54.69% (higher).

Diluted EPS

44.98INR

YoY

54.69%

Last updated:

Diluted Earnings per Share of IPCA Laboratories is 2026 44.98 INR. Diluted Earnings per Share of IPCA Laboratories was 2025 29.08 INR. It decreases by 54.69% higher compared to the previous year.

The IPCA Laboratories Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2019
17.59 INR
Jan 1, 2020
24.08 INR
Jan 1, 2021
44.92 INR
Jan 1, 2022
34.84 INR
Jan 1, 2023
18.58 INR
Jan 1, 2024
21.57 INR
Jan 1, 2025
29.08 INR
Jan 1, 2026
44.98 INR
The IPCA Laboratories Diluted EPS history
YEARDiluted EPSYoY
44.98INR+54.69%
29.08INR+34.78%
21.57INR+16.13%
18.58INR-46.68%
34.84INR-22.43%
44.92INR+86.49%
24.08INR+36.90%
17.59INR+85.81%
9.47INR+23.47%
7.67INR+108.87%
3.67INR-63.36%
10.02INR-46.87%
18.86INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Diluted Earnings per Share of IPCA Laboratories is 44.98 INR in 2026.

Diluted Earnings per Share of IPCA Laboratories changed from 29.08 INR to 44.98 INR, representing a 54.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — IPCA Laboratories

All Key Metrics — IPCA Laboratories